**IN VITRO ASSESSMENT OF COBALT OXIDE PARTICLE DISSOLUTION IN SIMULATED LUNG FLUIDS FOR IDENTIFICATION OF NEW DECORPORATING AGENTS**

Anne Van Der Meeren1\*, David Lemaire2, Sylvie Coudert1, Guillaume Drouet1, Myriam Benameur2, Célia Gouzerh1, Cien Yoong Hee4, Pauline Brunquet4, Bastien Trochaud2, Magali Floriani3, Christelle Gateau4, Colette Lebrun4, Pascale Delangle4, Catherine Berthomieu2 and Véronique Malard2\*

1: Laboratory of Radio Toxicology, CEA, Paris-Saclay University, 91297 Arpajon, France

2: Aix Marseille Univ, CEA, CNRS, BIAM, UMR7265, IPM, 13108 Saint Paul-Lez-Durance, France

3: Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-ENV/SRTE/LECO, Cadarache, 13115, Saint-Paul-lez-Durance, France

4: Univ. Grenoble Alpes, CEA, CNRS, IRIG, SyMMES, F-38000 Grenoble, France

\*Corresponding authors : Anne Van Der Meeren, Véronique Malard

\*e-mail: [anne.vandermeeren@cea.fr](mailto:anne.vandermeeren@cea.fr) - [veronique.malard@cea.fr](mailto:veronique.malard@cea.fr); ORCID ID: 0000-0002-0020-0518

Véronique Malard, DRF/BIAM bat 185, UMR 7265 CNRS CEA Aix-Marseille Univ. CEA-Cadarache

13108 Saint Paul-lez-Durance. TEL : +33 4 42 25 42 77 - FAX : +33 4 42 25 26 25

The authors declare that they have no conflict of interest.

**Acknowledgements**

The authors would like to acknowledge Carole Bresson (CEA/DEN), Nina Griffiths (CEA/DRF), Laurence Lebaron-Jacobs (CEA/DRF) and Simon Duval (CNRS/AMU) for fruitful discussions. This work was supported by the company Electricité De France (EDF).

**Abstract**

Inhalation of 60Co3O4 particles may occur at the work place in nuclear industry. Their low solubility may result in chronic lung exposure to γ rays. Our strategy for an improved therapeutic approach is to enhance particle dissolution to facilitate cobalt excretion, as the dissolved fraction is rapidly eliminated, mainly in urine.

*In vitro* dissolution of Co3O4 particles was assessed with two complementary assays in lung fluid surrogates to mimic a pulmonary contamination scenario. Twenty-one molecules and eleven combinations were selected through an extensive search in the literature, based on dissolution studies of other metal oxides (Fe, Mn, Cu) and tested for dissolution enhancement of cobalt particles after 1 to 28 days of incubation.

DTPA, the recommended treatment following cobalt contamination did not enhance 60Co3O4 particles dissolution when used alone. However, by combining molecules with different properties, such as redox potential and chelating ability, we greatly improved the efficacy of each drug used alone, leading for the highest efficacy, to a 2.7 fold increased dissolution as compared to controls. These results suggest that destabilization of the particle surface is an important initiating event for a good efficacy of chelating drugs, and open new perspectives for the identification of new therapeutic strategies.

**Keywords:** cobalt oxide particles, bioaccessibility, dissolution and chelating agents, lung, *in vitro*.

# **Introduction**

Cobalt (Co) is widely used in industrial processes for its magnetic properties, corrosion resistance, wear resistance, and/or its strength at elevated temperatures (Barceloux, 1999). The γ-emitter 60Co is a neutron activation product formed from structural materials in nuclear reactors. During procedures such as maintenance, 60Co can be released as highly mobile and highly radiant oxide particles. Accidental internal or cutaneous contamination of workers may thus arise (Davis et al., 2007; Le Guen and Ansoborlo, 2005). In addition to the risk of exposure for workers in the nuclear industry, 60Co has been identified as a potential candidate for use in a “dirty bomb” (Rump et al., 2018). Such a device could lead to the contamination of a great number of victims by fallout of radioactive dusts.

Cobalt oxide particles Co3O4 are poorly soluble compounds, classified as S (slow) by the International Commission on Radiological Protection (ICRP) based on the transfer rate from lungs to blood following pulmonary contamination (ICRP, 2016). Following inhalation of 57Co3O4 particles in baboons, only 40 % of initially deposited particles were cleared 6 months post-exposure (Kreyling et al., 1991). Short-term clearance resulted from particle transfer to the larynx, whereas, longer-term clearance was due to the translocation of dissociated Co to the blood. Once this dissolved Co fraction reaches the blood compartment, it is rapidly eliminated, with a Co half-life of 12 hours. More precisely, a recent study in rats has shown that 67.6% of cobalt administered as the soluble form , 60CoCl2, is excreted in urine with a half-life of 1.9 h, and 34.5% with a half-life of 45 h (Weber et al., 2012). The chemical toxicity of Co has been found higher for soluble compounds than for Co3O4 particles (Ortega et al., 2014). However, following inhalation of insoluble radioactive cobalt particles, long-term consequences such as lung fibrosis or lung cancer could occur as a result of its radiological toxicity.

Whatever the route of internal contamination by 60Co3O4 particles (60Co3O4P), the current recommendation for the management of contamination is the intravenous administration of Ca-DTPA (Diethylenetriamine-pentaacetic acid calcium trisodium salt hydrate) or EDTA (Ethylenediaminetetraacetic acid disodium salt dihydrate), although inhalation of DTPA can also be considered following lung contamination (ASN, 2008; REMM). Animal studies aiming at determining the efficacy of various drugs, including DTPA, have been carried out essentially following systemic contamination with soluble forms of cobalt (Fisher and Dunavant, 1978; Levitskaia et al., 2010a; Levitskaia et al., 2011; Levitskaia et al., 2010b; Llobet et al., 1986, 1988; Zylicz et al., 1975). Treatments with both DTPA and EDTA increased cobalt excretion and decreased cobalt retention in several tissues (Fisher and Dunavant, 1978; Llobet et al., 1986, 1988; Zylicz et al., 1975). Some success has also been obtained with molecules selected for their Co2+-binding properties, such as N-acetyl-l-cysteine, d or l-penicillamine, L-cysteine, trientine or glutathione (Levitskaia et al., 2010a; Levitskaia et al., 2011; Levitskaia et al., 2010b; Llobet et al., 1986, 1988). Some of these molecules, namely d-penicillamine and trientine, are also efficient treatments for copper detoxification in Wilson Disease (Delangle and Mintz, 2012). Human cases of cobalt toxicity have been reported following high serum concentrations of Co2+ resulting from leaching of Co-containing prostheses. Administration of N-acetyl-cysteine significantly decreased Co2+ concentration in blood (Giampreti et al., 2016) whereas EDTA had only at transient efficacy (Pazzaglia et al., 2011). Following inhalation of 60Co3O4P, the most likely scenario at the work place, chelation by DTPA is expected to concern mainly the ionized form of cobalt, Co2+, suggesting that DTPA treatment would have limited efficacy. Indeed, in case of inhalation of poorly soluble compounds, such as plutonium oxides, only the solubilized fraction present in lung fluids was accessible to DTPA (Gremy et al., 2010). To our knowledge, neither DTPA nor the other potential decorporating agent efficacy have ever been tested after exposure to cobalt oxides.

Decorporation aims at increasing excretion and reducing the retention of the contaminant. The main retention site following inhalation of cobalt particles is the lungs. Pulmonary clearance reflects a multi-stage process, integrating the dissolution of the contaminant, the interactions with (biological) ligands and the absorption into fluids. Inhaled particles are rapidly engulfed by macrophages, where they may remain trapped for long periods. The determining process in the transfer of Co from lungs to blood has been shown to be the intracellular dissolution of the Co particles in the macrophages (Kreyling et al., 1993). The Co2+ ionic species generated by the dissolution process become bioavailable to chelating drugs. Therefore, enhancing dissolution may represent the first step in the clearance of poorly soluble particles, by increasing the fraction of the contaminant available to chelating drugs. To fulfill the recommendations of the European directive 2010/63/EU, the principles of the “3Rs” (Replacement, Reduction and Refinement) must be considered systematically at all times when animals are used for scientific purposes. These principles were first proposed by Russell and Burch (Russell and Burch, 1959). They are currently proposed as the key strategies of a systematic framework aimed at achieving human use of any drugs. A recent paper demonstrates the applicability of the 3Rs in the field of radiotoxicology (Griffiths et al., in press), and particularly the use of adequate dissolution assays to provide information on solubility and bioaccessibility of various contaminants.

Whereas extensive literature on the dissolution of other oxide particles exists, only a few studies have been dedicated to the dissolution of Co3O4P (Cho et al., 2012; Collier et al., 1992; Lundborg et al., 1992; Ortega et al., 2014). Since the most likely scenario for accidental exposure at the work place is the inhalation of cobalt particles, our approach consisted in the evaluation of various categories of molecules for their efficacy in Co3O4P dissolution. We successively tested: 1- molecules for which an efficacy to decorporate soluble Co2+ has been previously described, 2- various known Co2+-binding molecules and 3- metal-binding sulfur-containing pseudopeptides. We then broadened our tests to molecules known for their ability to increase the dissolution of various metal oxides and to associations of molecules with complementary properties.

To foresee the use of these molecules in *in vivo* experiments and ultimately in man, FDA approved or non-toxic molecules were preferentially selected. The dissolution of a contaminant will depend on the intrinsic physicochemical properties of this contaminant as well as physicochemical and physiological properties of the biological environment, such as extra- and intra-cellular chemical constituents (Hedberg et al., 2010; Kastury et al., 2017; Pelfrene et al., 2017; Staack et al., 2017; Stefaniak, 2010). Thus, a large number of molecules was tested in media mimicking lung fluids, Gamble’s and ALF (Artificial Lysosomal Fluid), using a simple dissolution model in solution. Then, the molecules selected for their efficacy on Co3O4P dissolution were tested using a biphasic dynamic assay recently developed to assess the bioavailability of actinides (Van der Meeren et al., 2019). This assay was used to better mimic the transfer of bioavailable species from a retention compartment (agarose gel) to a dynamic phase (transfer compartment), where the drugs were added. Relevant physiological conditions were obtained by introducing various components both in the static and dynamic phases. In addition, the data obtained from this assay with actinides was found to show good correlation between dissolution data and urinary excretion following contamination in rat (Griffiths et al., 2016). In this work, this assay was used as a first assessment to predict the fraction of Co3O4P that could potentially be transferred from retention compartments to the blood, as well as the Co2+- fraction available to chelating drugs.

Co3O4P with sizes representative of those produced in nuclear reactors were chosen (Davis et al., 2007; Ortega et al., 2014). Finally, since a similar chemical behavior can be expected *in vitro* whatever the isotope, the present studies were conducted with the stable isotope, 59Co.

Altogether, the use of *in vitro* assays allowed the testing of a great number of molecules thus opening new perspectives for novel therapeutic approaches. This study could represent a benchmark for the development of similar approaches, to test the dissolution of other relevant metal oxide particles.

**Materials and Methods**

**Reagents**

Nitric acid and hydrochloric acid of high purity grade (HNO3 65% Suprapur and HCl 35% Suprapur) were purchased from VWR. Co2+ solution for the ICP-MS calibration curves were prepared from standard solutions (1 mg. L-1), which were purchased from SPEX (SPEX Certiprep Company).

Diethylenetriamine-pentaacetic acid (DTPA Ca), 1-Hydroxyethylidenediphosphonic acid (HEDP), diphenylethylene diamine (DPEN), triethylene tetramine (TRIEN), N-Acetyl-L-cysteine (NAC), L-cysteine, Ethylenediaminetetraacetic acid (EDTA), L-Glutathione (GSH), DL-Dithiothreitol (DTT), L-ascorbic acid, pyrocatechol, L-histidine, Imidazole, o-Phenylenediamine (OPD), 2,6-Pyridinedicarboxylic acid (DIPIC), Oxalate, Deferoxamine mesylate salt (DFOB), Deferiprone (DFP), Ferrichrome, L-ornithine, Thiamine hydrochloride, Enterobactin, Tannic acid and Desferrithiocine (DFT) were purchased from Sigma-Aldrich. Ca-DTPA from PCA (Pharmacie Centrale des Armées, France) was used for the dynamic biphasic assay.

To enhance the relevance of the study, whenever possible and for already clinically used molecules, the concentration of molecules were chosen according to the recommendations for human use. As an example the recommended for intravenous daily administration of DTPA is 15-30 µmole/kg depending of the body mass, which corresponds to roughly 500 µM in blood at the time of administration.

**Cobalt oxide particles preparation and characterization**

Cobalt particles (Co3O4P) were obtained from Sigma-Aldrich. The particle size (370 nm diameter) was chosen to be representative of particles involved in an incident at the work place for which a mean diameter was estimated to be of 410 nm (Davis et al., 2007).

Co3O4P were suspended in deionized water to prepare stock solutions with a cobalt concentration of 8 mg mL-1; suspensions were then sonicated for 15 min with an Autotune sonicator (Fisher Scientific; Illkirch, France) operated at 750 W, and stored at -20 °C until use as previously described (Ortega et al., 2014; Uboldi et al., 2016).

Co3O4P characterization after 28 days of incubation was performed using Transmission Electron Microscopy (TEM) analysis. Eight µl of particle suspension in ascorbate and DFOB were deposited on carbon film – 200 mesh copper grids, and examined in a Tecnai 12 G2 Biotwin scanning transmission electron microscope (Thermo Fisher Scientific, FEI Company, Eindhoven, the Netherlands) using an accelerating voltage of 100 kV and coupled with a Megaview III (Olympus Soft imaging Solutions GmbH, Münster, Germany). Particle size was analyzed using the Image J software (<https://imagej.nih.gov/>, v.1.52n).

**Metal-binding sulfur pseudopeptides**

Three metal-binding sulphur pseudopeptides were tested in the study. Their structure is based on polyaminocarboxylate scaffolds (NTA, EDTA or DOTA) grafted by 3 (for NTA) or 4 (for EDTA and DOTA) cysteine amide (Cys-NH2) residues (See Scheme S1). The synthesis of NTA(CysNH2)3 is reported in the literature (Pujol et al., 2011) and the two other derivatives, specifically designed for the study, EDTA(CysNH2)4 and DOTA(CysNH2)4 were obtained using similar synthetic procedures.

Their affinity for Co2+ was measured in competition experiments with NTA following the decrease of the intense UV-Vis absorption of the Co2+-thiolate complexes upon NTA addition. (See Supplementary Material).

**Preparation of incubation media**

All the solutions were prepared with deionized ultrapure water. Four media were used: 140 mM NaCl, 5 mM KCl (pH 5.6), HEPES 20 mM, NaCl 100 mM (pH 7.4), Gamble’s solution (pH 7.4) and Artificial Lysosomal Fluid (ALF, pH 4.5). Gamble’s and ALF were prepared according to Marques et al. (Marques et al., 2011). Buffers were filtered through a 0.22 μm cellulose membrane filter and degassed half an hour before use.

**Dissolution assay in solution**

1.2 mL of Co3O4P suspensions (1 mM Co) were prepared in medium containing various ligands at 500 µM concentration leading to ligand/cobalt ratios of 0.5, unless mentioned, and incubated at 37°C under stirring (37 rpm) for 1 to 28 days according to previous studies (Ortega et al., 2014; Weber et al., 2012). At each collection time, an aliquot of 500 µL of each sample was centrifuged 10 minutes at 16 000 g and the supernatant was filtered through a 0.1 µm syringe filter to eliminate remaining particles (Ortega et al., 2014). 100 µL of supernatant were diluted in HNO3 5% and analyzed by inductively coupled plasma mass spectrometry (ICP-MS, NexION 350X, PerkinElmer) equipped with an auto sampler and a crossflow nebulizer. The instrument was calibrated using 0.1, 0.5, 1, 2, 5, 10 and 20 parts per billion (ppb) of cobalt. To determine the amount of total cobalt in each sample, an aliquot of 100 µl of particles solution was collected at the beginning of the incubation, and analyzed by inductively coupled plasma mass spectrometry (ICP-MS after acid digestion with 30% HCl followed by 65% HNO3, as previously described (Ortega et al., 2014). Each experiment was performed at least in triplicate, each replicate being prepared from a different cobalt solution. The results were expressed as % of solubilized cobalt (solubilized cobalt *vs* total cobalt).

**Dissolution using the biphasic dynamic assay**

Agarose gels were prepared by dissolution of agarose powder type IIA (Sigma) as a 2.5% solution in physiological saline (140 mM NaCl, 5 mM KCl, pH 5.6), ALF or Gamble’s solutions as described (Van der Meeren et al., 2019). The agarose solution was melted by heating in a microwave, and Co3O4P were added under gentle stirring at the final Co concentration of 0.13 mM in gels. A ligand:cobalt ratio of 3.8 was used whatever the molecules, alone or in combination. The agarose solution was then distributed in 24 well-culture dishes, representing the static phase. After the gel had hardened, the dynamic phase was added in the wells. The plates were then incubated at 37°C in a 5% CO2 atmosphere on an orbital shaker. At the end of the experiment, the samples were collected, digested with concentrated ultrapure chlorhydric and nitric acid. Digested samples were diluted in HNO3 1% and analyzed using ICP-MS (NexION 350X, PerkinElmer or ICAPQ Thermo). The calibration was conducted with 0.1, 0.5, 2, 10, 20, 50 µg/L standards prepared in HNO3 1%. Gallium (Analab) was used as internal standard. All conditions were done in triplicate.

The principle of the biphasic assay is based on the hypothesis that bioavailable ions would migrate into the dynamic fluid phase, while particles or complexes formed with biological ligands would remain trapped in the static phase. The validation of our assay was done using actinides (Griffiths et al., 2016; Van der Meeren et al., 2019). To ensure that it was also applicable to cobalt, we compared the transferability of different chemical forms of cobalt incorporated in the gel. Our results (shown in Figure S1) demonstrate the low retention of CoCl2 in the static phase (20% in 7 days) as opposed to the high retention of particles (> 99% on 7 days). In addition, to make sure that only Co2+ ions were transferred in the dynamic phase following the dissolution of particles, the dynamic phase was filtered through 100 nm diameter pore filters. Cobalt concentrations measured in the filtered samples did not differ from those of the non-filtered samples (data not shown).

**Statistical Analysis**

Results are expressed as mean ± SD. One-way ANOVA followed by Dunnett’s multiple comparisons test were performed using GraphPad Prism version 8 (GraphPad Software; La Jolla, CA, USA).

**Results**

**1/Intrinsic Co3O4P dissolution rate in NaCl, Hepes, ALF and Gamble’s.**

We first evaluated the intrinsic dissolution properties of Co3O4P in HEPES and NaCl/KCl, for a 7-day incubation period. Next, Gamble’s solution and ALF were used, as the common surrogate fluids of the main lung retention compartments. Gamble’s solution mimics the interstitial and airway lining fluids, whereas ALF simulates intracellular conditions in phagocytes, such as macrophages (Marques et al., 2011).

A low solubility of Co3O4P was observed in the HEPES medium for which no interaction/complexation with ligands occurred. Less than 0.2 % of Co2+ was released over the 7-day incubation period (Figure 1A). Dissolution was even lower in Gamble’s, with less than 0.02% cobalt dissolution over 7 days. A significantly higher dissolution was observed in ALF, with 0.7 % dissociated cobalt after a one-day incubation period and up to 4.3% after 7 days (Figure. 1A). Similar results were obtained with the biphasic dynamic assay although a lower dissolution was measured in ALF (2.6% in 7 days) (Figure 1B). Both the presence of citrate and low pH could explain the higher dissolution in ALF.

****

***Figure 1: Dissolution of Co3O4P.***

*Co3O4P dissolution was assessed in solution. (A), Co3O4P particles were incubated 1 day and 7 days, in HEPES, Gamble’s and ALF. Results are expressed as mean % ± SD of solubilized Co versus total cobalt. In the two-phase dynamic assay, (B), Co3O4P were included in gels prepared in NaCl/KCl, ALF or Gamble’s. Results are expressed as mean % ± SD of cumulative Co measured in the dynamic phase versus initial Co in the gel. Each experimental condition was done in triplicate and repeated 3 times.*

**2/ Molecules showing Co2+-decorporating efficacy: effect on Co3O4P dissolution**

Various molecules, all being Co2+- ligands with different affinities (Table S1), have shown some efficacy for decorporation of soluble forms of cobalt in rats (Levitskaia et al., 2011; Levitskaia et al., 2010b; Llobet et al., 1986, 1988). However, none of these molecules have been tested for decorporation of poorly soluble Co3O4P. Therefore, using the dissolution assay in solution, we evaluated the ability of these ligands to increase Co3O4P dissolution in the lung fluids surrogates Gamble’s and ALF, as well as in HEPES. The efficacy of the different drugs N-acetyl-L-cysteine (NAC), EDTA, L-cysteine (L-cys), glutathione (GSH), N,N-bis (2-aminoethyl) -1,2-ethanediamine dihydrochloride (Trien) and D-penicillamine (D-PEN) was assessed and compared to that of DTPA, as DTPA is currently the recommended treatment in case of accidental internal contamination with Co3O4P (ASN, 2008; Giampreti et al., 2016).

In HEPES, a statistically significant increase in Co3O4P dissolution was observed at day 7 with all the tested molecules except TRIEN (Figure 2A). The highest efficacy was obtained with EDTA leading to 2.2% dissolution (*p*<0.001) at day 7. In contrast, none of the tested molecules induced a statistically significant increase in Co3O4P dissolution in Gamble’s except the two sulphur-containing molecules, L-cys and to a lower extent GSH (Figure 2B). However, the percentage of Co3O4P dissolution remained very low (< 0.05%). In ALF, no increase in particle dissociation was observed whatever the drug tested (Figure 2C) as compared to the untreated controls.



***Figure 2: Effect of Co2+-decorporating agents on Co3O4P dissolution****.*

*Co3O4P were incubated for 1 or 7 days in HEPES, Gamble’s and ALF. At the end of the incubation, Co concentration was measured in the supernatant. Results are expressed as mean % ± SD of dissolved Co/ total cobalt. Each experimental condition was done in triplicate. Statistically significant differences from control were determined by one-way ANOVA followed by Dunnett's multiple comparisons test: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.*

Experiments using the dynamic biphasic assay (Figure 3) confirmed the absence of significant increase in Co3O4P dissolution with DTPA in the lung fluid surrogates Gamble’s and ALF. A slight and transient enhanced dissolution was seen in the presence of DTPA as compared to non-treated controls in NaCl (p< 0.001) at day 4.



***Figure 3: Effect of DTPA on the dissolution of Co3O4P assessed in the two-phase dynamic assay.*** *Co3O4P were included in the static retention phase (agarose gels) prepared in NaCl, Gamble’s or ALF. DTPA 500 µM was added in the dynamic phase. Results are expressed as mean % ± SD of cumulative cobalt transferred in the dynamic phase/initial cobalt in the gel. Each experimental condition was done in triplicate and repeated 1 to 3 times. \*\*\*p < 0.001.*

The contrasting results obtained using both assays in the non-physiologic buffers and in the lung surrogates (Gamble’s and ALF) highlight the importance of using biologically-relevant media for dissolution studies, as also previously reported by others (Kastury et al., 2017).

**3/ Molecules with reported properties for cobalt chelation or for metal oxide particles dissolution**

The absence of effect of the above tested molecules on Co3O4P dissolution in lung fluid surrogates is likely to predict a low decorporation efficacy of those drugs following pulmonary contamination with Co3O4P.

Therefore, from an exhaustive review of the literature summarized in Table 1, we selected various molecules with metal chelating properties as well as molecules enhancing other metal oxide particle dissolution.

***Table 1****: Literature review of molecules involved in metal oxide dissolution*

|  |  |  |  |
| --- | --- | --- | --- |
| Acting molecule | Metal (form) | Chemical effect | Reference |
| Ascorbate | Fe (Fe2O3, Fe3O4)  Mn oxides | Redox, chelation Reductive dissolution | Huang et al. 2017  Joseph et al. 1996  Afonso et al. 1990  Suter et al. 1991  Panias et al. 1996  Stone et al. 1984 |
| Ascorbate + EDTA | Fe (Fe2O3, Fe3O4) | Auto accelerated reductive dissolution | Afonso et al. 1990 |
| Ascorbate + oxalate | Fe (Fe2O3, Fe3O4) | Reductive dissolution and chelation | Afonso et al. 1990 |
| Catechols | Mn oxides | Reduction and chelation | Stone et al. 1984 |
| Citrate | Fe (Fe2O3) | pH | Joseph et al. 1996 |
| Combination CEA (citrate, ascorbate, EDTA) | Fe (Fe(III)2O3) | Ligand assisted reductive dissolution | Joseph et al. 1996  Anathan et al. 2003 |
| DFOB | Co (CoOOH)  Fe (oxides)  Fe (Cr(III)-Fe(III)-(oxy)hydroxides) | Redox Chelation | Bi et al. 2010  Kraemer. 2004  Saad et al. 2017 |
| DFOB + oxalate | Fe (Cr(III)-Fe(III)-(oxy)hydroxides)  Al (Fe3O4) | Redox, chelation | Saad et al. 2017  Cervini-Silva et al. 2002 |
| DIPIC (2,6-pyridinedicarboxylate) | Co (Co(II), Co(III)) | Chelation | Yang et al. 2002 |
| enterobactin | Fe (Fe-OOH) | Ligand metal affinity and adsorbtion | Dubbin et al. 2017 |
| Ferrichrome | Fe (Fe-OOH) | Ligand metal affinity and adsorbtion | Dubbin et al. 2017 |
| HEDP | Co (II) | Ligand | Jurisson et al. 1983 |
| Histidine | Co (II) | Ligand | Bornhost et al. 2000 |
| Oxalate | Fe (oxides) | Redox, chelation | Kraemer. 2004  Panias et al. 1996  Zinder et al. 1986 |
| phenolic reductants (catechol) | Fe (FeOOH, Fe2O3) | redox | Lakind et al. 1989 |
| Tannic acid | Cu (CuO NPs) | chelation | Zhao et al. 2017 |

A total of 32 assays were carried out using the dissolution assay in solution for efficacy testing of a total of 21 molecules and 11 different combinations. This screening was done in Gamble’s and ALF given the lack of consistency between results obtained in HEPES saline solution and lung fluid surrogates.

Co2+ was measured at days 1 and 7 (Table 2). For ALF, in the absence of added molecules, the percentage of dissolution differed between experiments (from 0.57 to 0.85% at day 1 and from 2.9 to 4.9% at day 7). Therefore, to allow a comparative evaluation of dissolution efficacy in ALF, we used the percentage of dissolution measured in the presence of the molecule tested divided by the percentage of dissolution observed in the related control, to calculate a ratio. This calculation mode was not necessary for results obtained in Gamble’s, because of lower day variability. Thus, results obtained in Gamble's were expressed as % of solubilized cobalt/ total cobalt content.

The tested molecules were classified in different categories: Co2+- ligands, high SH-containing ligands and molecules enhancing metal oxide dissolution. Association of molecules from these categories were also tested (Table 2). Our results will be described in the following paragraphs, according to the category of the tested molecules.

***Table 2****: Dissolution of Co3O4P in the presence of various molecules assessed in Gamble’s and ALF using the dissolution assay in solution.*

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **GAMBLE'S** | | | | | | **ALF** | | | | | |
|  | **% dissolved Co/total Co** | | | | | | **fold increase dissolution treated/untreated** | | | | | |
|  | **(mean % ± SD)** | | | | | | **(mean ratio ± SD)** | | | | | |
| **Ligand** | **DAY 1** | | | **DAY 7** | | | **DAY 1** | | | **DAY 7** | | |
| 0 | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.00 |  |  | 1.00 |  |  |
| DTPA | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.03 | ± | 0.02 | 1.00 | ± | 0.05 |
| **COBALT LIGANDS** | | | | | | | | | | | | |
| DIPIC | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.06 | ± | 0.03 | 1.07 | ± | 0.13 |
| HEDP | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.91 | ± | 0.01 | 1.01 | ± | 0.04 |
| Histidine | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.82 | ± | 0.09 | 1.00 | ± | 0.13 |
| **HIGH -SH LIGANDS** | | | | | | | | | | | | |
| DOTA(CysNH2)4 | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.14 | ± | 0.01 | 0.90 | ± | 0.02 |
| EDTA(CysNH2)4 | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.11 | ± | 0.03 | 0.89 | ± | 0.01 |
| NTA(CysNH2)3 | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.13 | ± | 0.07 | 1.06 | ± | 0.11 |
| **MOLECULES ENHANCING METAL OXIDE DISSOLUTION** | | | | | | | | | | | | |
| Asc | 0.11% | ± | 0.01 | ≤ 0.1% |  |  | **1.95** | ± | **0.09** | **1.41** | ± | **0.03** |
| Asc + EDTA | **0.88%** | **±** | **0.13** | **0.91%** | **±** | **0.12** | **2.21** | ± | **0.16** | **1.38** | ± | **0.09** |
| Asc + oxalate | ≤ 0.1% |  |  | ≤ 0.1% |  |  | **2.41** | ± | **0.10** | **1.65** | ± | **0.13** |
| DFOB | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.24 | ± | 0.04 | **1.38** | ± | **0.04** |
| DFOB + oxalate | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.21 | ± | 0.06 | **1.50** | **±** | **0.10** |
| DFP | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.28 | ± | 0.04 | 1.11 | ± | 0.04 |
| DFT | ND |  |  | ND |  |  | 1.03 | ± | 0.01 | **1.32** | ± | **0.20** |
| Enterobactin | **0.34%** | **±** | **0.03** | **0.47%** | **±** | **0.06** | **1.32** | **±** | **0.09** | 1.16 | ± | 0.06 |
| Ferrichrome | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.97 | ± | 0.01 | 1.16 | ± | 0.40 |
| Oxalate | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.95 | ± | 0.03 | 1.25 | ± | 0.07 |
| Pyrocatechol | ≤ 0.1% |  |  | ≤ 0.1% |  |  | **1.39** | **±** | **0.05** | 1.26 | ± | 0.05 |
| Tannic acid | ND |  |  | ND |  |  | 1.78 | ± | 0.01 | 1.27 | ± | 0.10 |
| **NEW TESTS OR COMBINATIONS** | | | | | | | | | | | | |
| Asc + DFOB | **0.16%** | **±** | **0.03** | **0.16%** | **±** | **0.01** | **1.87** | **±** | **0.13** | **1.59** | **±** | **0.16** |
| Asc + DOTA(CysNH2)4 | **0.55%** | **±** | **0.04** | **0.61%** | **±** | **0.01** | **1.97** | **±** | **0.06** | 1.27 | ± | 0.06 |
| Asc + DTPA | **0.55%** | **±** | **0.39** | **0.54%** | **±** | **0.36** | **2.07** | **±** | **0.26** | **1.45** | **±** | **0.14** |
| Asc + EDTA(CysNH2)4 | **0.28%** | **±** | **0.04** | **0.33%** | **±** | **0.01** | **1.81** | **±** | **0.32** | 1.08 | ± | 0.09 |
| Asc + EDTA Na + OPD | **0.94%** | **±** | **0.08** | **0.99%** | **±** | **0.17** | **2.11** | **±** | **0.07** | **1.30** | **±** | **0.01** |
| DIPIC + Hist | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.84 | ± | 0.04 | 1.02 | ± | 0.01 |
| DIPIC + L-ornithine | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.90 | ± | 0.01 | 1.14 | ± | 0.05 |
| DIPIC + OPD | ≤ 0.1% |  |  | ≤ 0.1% |  |  | **1.95** | **±** | **0.09** | 1.18 | ± | 0.05 |
| DIPIC + Thiamine | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 1.06 | ± | 0.04 | 1.27 | ± | 0.02 |
| DTT | ND |  |  | ND |  |  | 1.14 | ± | 0.03 | 1.22 | ± | 0.13 |
| Imidazole | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.91 | ± | 0.03 | 1.10 | ± | 0.13 |
| L-cysteine + EDTA | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.91 | ± | 0.05 | 0.85 | ± | 0.09 |
| L-ornithine | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.88 | ± | 0.00 | 1.10 | ± | 0.11 |
| OPD | ≤ 0.1% |  |  | ≤ 0.1% |  |  | **1.96** | **±** | **0.09** | 1.14 | ± | 0.10 |
| Thiamine | ≤ 0.1% |  |  | ≤ 0.1% |  |  | 0.94 | ± | 0.01 | 1.14 | ± | 0.13 |

*In Gamble's, results are expressed as mean % ± sd (Co2+/ total cobalt content). Each experimental condition was done in triplicate and repeated 1 to 11 times. Percentages above 0.1 are shown in red and bold characters. In ALF, to allow a comparative evaluation of dissolution efficacy, we used the percentage of dissolution measured in the presence of the molecule tested divided by the percentage of dissolution observed in the related control, to calculate a ratio. Results are expressed as mean ±sd. Ratios above 1.3 are shown in red and bold characters. ND: not determined*

**3.1/ Effect of cobalt ligands and SH-rich ligands on Co3O4P dissolution**

The first category of selected molecules included cobalt ligands listed in Table 1.Both histidine, DIPIC (2,6-pyridinedicarboxylate) and HEDP (1-Hydroxyethylidenediphosphonic acid) are known Co2+-ligands (Bornhorst and Falke, 2000; Jurisson et al., 1983; Yang et al., 2002). In our hands, these molecules had no influence on Co3O4P dissolution neither in Gamble’s nor in ALF (Table 2).

The second category of chosen molecules were SH-rich ligands, since sulfur-containing molecules, i.e L-cys and NAC induced a low but significant increase in Co3O4P dissolution in Gamble’s (Figure 2). We synthesized sulphur pseudopeptides bearing a larger number of sulphur atoms in their chelating scaffolds, in an attempt to enhance the dissolution effect observed in Gamble’s with the monothiol molecules. These sulfur-containing pseudopeptides are polydentate ligands built on NTA, EDTA and DOTA, grafted which three to four cysteines. The structures of the three pseudopeptides are reported in Scheme S1 together with their affinity for Co2+ measured at physiological pH. NTA(CysNH2)3 is a trithiol ligand previously designed for metal chelation, demonstrating a large affinity for Cu+ and to a lesser extent for Zn2+ (Pujol et al., 2009, 2011). It forms a CoL complex with a micromolar affinity at pH 7.4, which is significantly larger than the affinities reported for Co2+ with l-cys and GSH (Table S1). The two other pseudopeptides derived from EDTA and DOTA. EDTA(CysNH2)4 and DOTA(CysNH2)4, that were specifically designed for this study, have four thiolates in their structure. As expected, their affinity for Co2+ is larger than with NTA(CysNH2)3 since Co2+ is known to be efficiently coordinated in a tetrahedral tetrathiolate coordination environment. Their CoL complexes exhibit stabilities in the nanomolar range at pH 7.4, the cyclic DOTA derivative demonstrating a slightly larger affinity. It has to be noted that the two latter sulphur-rich ligands are able to complex a second Co2+ ion probably through the N/O atoms of the chemical scaffold in a Co2L complex. However, despite their enhanced affinity for Co2+ with respect to monothiol molecules, none of these sulfur pseudopeptides led to an increased Co3O4P dissolution whatever the medium used (Table 2).

**3.2/ Effect of molecules enhancing metal oxide dissolution on Co3O4P dissolution.**

Since none of the molecules tested above were able to induce significant increase in the dissolution of Co3O4P, we selected other molecules from literature (Table 1) which, alone or in combination, have been shown to induce a strong dissolution of metallic oxides particles of iron, copper, or manganese. We also tested the effect of ligands susceptible of releasing protons, since protons (or low pH) have a strong effect on metallic oxide particle dissolution.

The role of metal ion reduction on particle dissolution has been demonstrated with ascorbate (Afonso et al., 1990; Huang et al., 2017; Joseph et al., 1996; Panias et al., 1996; Stone and Morgan, 1984; Suter et al., 1991), oxalate (Kraemer, 2004; Panias et al., 1996; Zinder et al., 1986) and with phenolic reductants as catechol (Lakind and Stone, 1989) or tannic acid (Zhao et al., 2017). These compounds have been shown to increase the dissolution of metal oxides, such as Fe and Mn by reduction. Some of these molecules seem to act through combined reductive and metal-binding effects. Moreover, association of different kinds of molecules was shown to induce efficient particle dissolution, such as ascorbate with oxalate or EDTA as well as with a mixture of citric acid and EDTA (Afonso et al., 1990; Joseph et al., 1996). It should be mentioned that all these studies were performed in non-physiologic buffers and mainly at acidic pH (≤ 4). In the present study, tannic acid, pyrocathecol and ascorbate alone or in association with oxalate or with EDTA significantly enhanced Co3O4P dissolution in ALF. The highest efficacy was obtained with the association of ascorbate and oxalate (2.41 fold increase as compared to controls at day 1 and 1.65 fold at day 7, these ratios corresponding respectively to 1.6 and 5.2% of dissolution). However, this association had no effect in Gamble’s. The association of ascorbate and EDTA increased significantly the dissolution of Co3O4P in both lung fluid surrogates, reaching 0.91% dissolution in Gamble's and a ratio to a 1.38 fold increase as compared to controls in ALF at day 7 (Table 2 ). It is interesting to keep in mind that citrate is one of the components of ALF. Except for the combination of ascorbate and EDTA, no other significant increase in Co3O4P dissolution was observed in Gamble’s (Table 2).

Siderophore-promoted dissolution has also been described for iron oxides. Dubbin et al., described an increase in iron release from synthetic goethite in the presence of ferrichrome and enterobactin at pH 6.5 (Dubbin and Bullough, 2017). Desferrioxamine B (DFOB) has been shown to increase Fe release from Cr(III)-Fe(III)-(oxy)hydroxides in an HEPES buffer at pH 7, and oxalate acted synergistically with DFOB to increase the Fe release (Saad et al., 2017). Bi et al demonstrated the solubilizing effect of DFOB on heterogenite in a pH dependent manner (Bi et al., 2010). We thus tested four siderophores: DFOB, enterobactin, desferrithiocin (DFT) and deferiprone (DFP). In Gamble’s, only enterobactin induced an increase in Co3O4P dissolution (0.47% dissolution at day 7). In ALF, both enterobactin and DFOB slightly enhanced dissolution. DFOB induced a 1.38 fold higher dissolution than that of controls at day 7, which is consistent with published data obtained for heterogenite particles (Bi et al., 2010). The two other siderophores, DFT and DFP also increased the dissolution of Co3O4P in ALF but to a lesser extent than DFOB (Table 2).

Saad et al. demonstrated that siderophore and oxalate promoted dissolution of Cr(III)-Fe(III)-(oxy)hydroxides (Saad et al., 2017). By using this combination, we reached a 1.5 increase in Co3O4P dissolution in ALF at day 7 as compared to the controls, which makes this combination one of the best candidates (Table 2).

**3.3/ Effect of novel molecule associations on Co3O4P dissolution**

Altogether, the above reported results highlight the improved efficacy of associations of molecules with complementary properties such as metal reduction and strong Co2+-binding properties as compared to each molecule alone. We thus tested molecules not reported in the literature for metal oxides dissolution but for which intrinsic properties might enhance the dissolution of cobalt particles.

We first tested dithiothreitol (DTT) for its strong reducing properties. Howewver, DTT showed a lower efficacy to dissociate Co3O4 particles than ascorbate in ALF (Table 2). In contrast, L-Cys, which is also a reductant, was shown to slightly increase Co3O4P dissolution in Gamble’s (Figure 2B). Thus, we evaluated the efficacy of a combination of ascorbate or L-Cys and high affinity Co2+ ligands (Table 2). The combination of L-cys with EDTA did not improve Co3O4P dissolution. Therefore, we focused on combinations involving ascorbate and cobalt ligands with different coordinating atoms and affinities (Table S1).

We did not observe any significant synergistic effect between ascorbate and DFOB. In contrast, the addition of ascorbate to the SH-rich pseudopeptides DOTA(Cys)4 and EDTA(Cys)4 led to 0.61% and 0.33% dissolution respectively at day 7 in Gamble’s, showing a good synergistic effect as compared to each molecule used alone. This effect was not observed in ALF. In Gamble’s we observed a strong synergistic effect with ascorbate and DTPA as compared to DTPA alone with 0.54% of dissolution at day 7 versus <0.1% for DTPA alone. This was not the case in ALF.

The combination of ascorbate with EDTA was one of the most effectives in Gamble’s, with 0.91% of dissolution at day 7. Since the affinity of DTPA for Co2+ is larger than that of EDTA (Table 1. Sup mat), the affinity for Co2+ does not seem to be the determining factor for an effective dissolution of Co3O4P in the lung fluid surrogates.

pH or the ability to deliver protons at the particle surface has also been reported as important factors in particle dissolution. A low pH however may prevent efficient chelation of Co2+ by chelating groups with mid or high pKA values. Dipicolinic acid (DIPIC) was shown to be of interest, as the [Co(dipic)2]2- complex is stable even at low pH due to the low basicity of the nitrogen atom found in the aromatic heterocycle (Yang et al., 2002). In addition, combination of DIPIC with proton acceptors (histidine, thiamine, ornithine and o-phenylenediamine, OPD) were described to enhance and stabilize the formation of the [Co(dipic)2]2- complexes at low pH (Ghasemi et al., 2014). However, no significant effect of these combinations was observed on the dissolution of Co3O4P in Gamble’s or in ALF (Table 2). In contrast, OPD alone had a slight effect in ALF. Therefore, we also tested OPD in combination with ascorbate and EDTA. OPD addition significantly increased Co3O4P dissolution efficacy in Gamble’s, with a dissolution ratio of 0.94% and 0.99% at day 1 and day 7, respectively, but not in ALF. Whereas it should be noted that addition of OPD markedly increased the efficacy of ascorbate and EDTA, those combinations were not retained for the rest of the study due to the toxicity of OPD (Matsumoto et al., 2012).

In summary, the best combinations of molecules are: ascorbate alone, DFOB alone and the combination of ascorbate with EDTA, ascorbate with oxalate, ascorbate with DTPA, ascorbate with DFOB and DFOB with oxalate.

**3.4/ Influence of ligand concentration on Co3O4P dissolution.**

We studied then the impact of DTPA or EDTA concentration in both lung fluids when used in association with ascorbate. Indeed, a strong effect of EDTA concentration on the dissolution of hematite in citric acid-EDTA-ascorbic acid mixtures has been previously observed (Joseph et al., 1996). The concentration of EDTA and DTPA was increased up to 50 mM. Whereas this high concentration has no physiological relevance, this study was made to identify the importance of Co2+-chelation in the dissolution process. By increasing 100 fold the EDTA concentration (50 mM), the percentage of dissolution increased by a factor of 5 (from 0.8% to 4%) in 7 days in Gamble’s (Figure 4). In ALF, only a slight but significant increase was observed. These results are in agreement with what was described with hematite in citric acid-EDTA-ascorbic acid mixtures (Joseph et al., 1996). Noticeably, raising DTPA concentration led to only a moderate increase in Co3O4P dissolution in Gamble’s. The decrease in dissolution observed in ALF as compared to the lower DTPA concentration of 0.5 mM, suggests different mechanisms of action for the two ligands.

****

***Figure 4: Impact of ligand concentration on particle dissolution at day 7 in Gamble’s and ALF.*** *Cobalt concentration remained constant while the ligand concentrations were increased from 0.5 to 50 mM, leading to ligand:cobalt ratios varying from 0.5 to 50 respectively. Results are expressed as mean % ± SD of dissolved cobalt/ total cobalt content. n=3. Statistically significant differences from control were determined by one-way ANOVA followed by Dunnett's multiple comparisons test: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.*

**4/ Long-term effect of various combinations on Co3O4P dissolution.**

To evaluate the long-term effect, the dissolution assay with the best combination of molecules was conducted in solution over 28 days,. This could confirm the interest of chronic decorporation treatment as it has been observed with DTPA after actinide pulmonary contamination (Guilmette and Muggenburg, 1993).

Our results show that increasing the incubation time further increased Co3O4P dissolution for most of the conditions in Gamble’s and for all in ALF. Ascorbate with EDTA 50 mM, in Gamble's, led to 8.2 +/- 1.8% dissolution although in the controls, soluble cobalt remained barely detectable (Figure 5). In ALF, although the Co3O4P dissolution in the controls was already of 18 +/-3% in 28 days, the dissolved fraction was much larger and reached 48 +/- 8%, 43 +/-1% and 40 +/-10% with the ascorbate and DFOB, oxalate and DFOB and DFOB alone, respectively (Figure 5). A progressive and constant dissolution occurred with time whatever the fluid surrogate in which particles were incubated, particularly in presence of DFOB.



***Figure 5: Dissolution of Co3O4P up to 28 days incubation with selected ligand combinations.*** *Results are expressed as mean % ± SD of dissolved cobalt/ total cobalt content, n=6.*

Since 48% of the cobalt was released from particulate matter after an incubation period of 28 days by ascorbate and DFOB in ALF, a decrease in particle size was expected to occur. Indeed, TEM analysis showed that the mean size of particles was significantly smaller when incubated in ALF for 28 days in the presence of ascorbate and DFOB as compared to controls in ALF alone (mean size 129 +/- 59 nm *vs* 157 ± 69 nm , p<0.01), (Figure 6).



***Figure 6: Co3O4P size after a 28 day incubation with ascorbate and DFOB.***

*A: TEM pictures were analyzed with Image J software to determine the diameter of particles in each sample (n=113). B: representative TEM picture of Co3O4P after a 28-day incubation with ascorbate and DFOB.*

**5/ Validation of the results using the two-phase model**

To go further in the determination of efficacy of various drugs to enhance particle dissolution, we used the dynamic two-phase model assay to assess the efficacy of molecules selected from the dissolution assay in solution. For this assay, the static phase representing the retention compartments was prepared in NaCl, Gamble’s or ALF. The molecules to be tested were added to the dynamic phase representing the transfer compartment.

Efficacy was assessed by measurement of Co in the dynamic phase from 1 to 7 days after incubation in saline or lung surrogates. Co3O4P dissolution was increased in the presence of ascorbate whether or not associated with other molecules (Figure 7). Oxalate did not increase dissolution of Co3O4P in ALF and Gamble’s when used alone, nor improved the efficacy of ascorbate when used in association. DFOB used alone was able to increase the dissolution of Co3O4P whatever the composition of the agarose gels. Remarkably, the higher efficacy, observed both in Gamble’s and ALF, was obtained with the association of the reductant ascorbate with the chelating agents DTPA or EDTA. These results confirm those obtained with the dissolution assay in solution.



***Figure 7: Effect of various molecules on dissolution of Co3O4P assessed in the two-phase dynamic assay.***

*Co3O4P were included in the static retention phase (agarose gels) prepared in NaCl/KCl (7A), Gamble’s (7B) or ALF (7C). Treatments (500 µM) were added in the dynamic phase. Results are expressed as % cumulative cobalt measured in the dynamic phase/initial cobalt in the gel. Each experimental condition was done in triplicate and repeated 1 to 3 times.*

As a summary, a schematic classification of the combinations with the highest efficacy at day 7 using both dissolution methods is presented in Table 3. Altogether, ascorbate associated with DTPA, EDTA and DFOB showed the highest efficacy on Co3O4P dissolution in both media.

***Table 3****: Schematic overview of the dissolution of Co3O4P in the presence of various molecules assessed in Gamble’s and ALF at day 7.*

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | DTPA | Asc | DFOB | Ox | Asc/DTPA | Asc/EDTA | Asc/DFOB | Asc/ox |
| Gamble’s | = | + | + | = | +++ | +++ | ++ | + |
|  |  |  |  |  |  |  |  |
| ALF | = | + | ++ | = | ++ | ++ | ++ | ++ |

*The combinations with highest efficacies in both media are shown in red.*

**Discussion**

Understanding the fate of poorly soluble inhaled compounds and the mechanisms controlling particle retention and clearance from the lungs is essential to evaluate the risk of long-term exposure and to develop tailored decorporation strategies. Following inhalation of poorly soluble compounds, such as Co3O4P, particle dissolution, occurring mainly in macrophages, represents the first step in lung clearance. In case of inhalation of strong gamma emitters 58Co or 60Co, the reduction of the retention time is of crucial importance to avoid chronic irradiation of target cells. Once the ionic form Co2+ is released by particle dissolution, it is expected to be rapidly eliminated from the body, mainly in urine. Indeed clearance of almost 100% after injection of CoCl2 occurs in 45 h (Weber et al., 2012). To accelerate urinary excretion, the use of chelating drugs is recommended. It is generally assumed that ionic forms are more prompt to form complexes with biological ligands or chelating agents than particulate forms, highlighting further the importance of increasing particle dissolution.

In the present study, our goal was to propose innovative strategies for Co3O4P dissolution, as a first step of decorporating drug development. The novelty of our work is four fold: 1- the use of particles with similar properties than those involved in a real accidental exposure at the work place, 2- the use of two complementary *in vitro* dissolution assay, the second one showing good correlation with *in vivo* excretion data following contamination with actinides, 3- the evaluation of efficacy of molecules differing in their mechanisms of action and 4- the evaluation of efficacy on dissolution Co3O4P, in biologically-relevant conditions, representative of an inhalation scenario.

The dissolution assessment consisting in measuring the ionic fraction of cobalt in solution at different times after incubation allowed the screening of a large number of molecules, used alone or in combination in simple buffer as well as in lung fluid surrogates. On the other hand, the dissolution assessment in the dynamic bi-compartmental assay, mimicking a retention phase and a transfer compartment is expected to give a good correlation with *in vivo* data (Griffiths et al., 2016). Using these two assays, we confirmed the low dissolution potential of Co3O4P in simple buffers, in the absence of interactions with chemical or biological entities (Collier et al., 1992). Using lung fluids surrogates, we showed that dissolution of Co3O4P was influenced by various parameters such as pH or the presence of compounds as citrate, carbonate, proteins, etc…, in line with results obtained for a number of metal oxide particles (Kastury et al., 2017; Pelfrene et al., 2017). The higher Co3O4P dissolution in ALF, representing the intracellular compartment of macrophages, likely results from the lower pH of this medium (pH 4.5 *vs* pH 7.4 in HEPES and Gamble’s) and the presence of citrate, since both parameters have been shown to facilitate dissolution of cobalt oxides (Collier et al., 1992; Lundborg et al., 1992). Co3O4P dissolution measured in the present study in ALF was of the same order of magnitude than previously reported (Cho et al., 2012; Collier et al., 1992; Ortega et al., 2014). The contrasting results obtained in buffers as compared to lung fluid surrogates, (Figures 2 and 3) underlined the need for using surrogates of relevant biological fluids for such studies.

We evaluated the efficacy of various molecules to increase Co3O4P dissolution, including DTPA as a gold standard, since this chelating agent is the recommended treatment following internal contamination with cobalt. In lung fluids, no dissolution enhancement was observed on Co3O4P dissolution with DTPA, nor in the presence of molecules previously described by others for their efficacy to decorporate soluble Co2+ (Figures 2 and 3). Further testing with specifically designed molecules with high-affinity for Co2+ or known Co2+ binding molecules (listed in Table 1) did not improve Co3O4P dissolution either. In addition, since the affinity of DTPA for Co2+ is larger than that of EDTA (Table 1. Sup mat), and the Co3O4P dissolution less efficient with DTPA than EDTA, the affinity for Co2+ does not seem to be the determining factor for an effective dissolution of Co3O4P in the lung fluid surrogates. These result strongly suggest that chelation of cobalt at the surface of the Co3O4P or destabilization of the particle surfaces are determining factors, and that molecules efficient for Co2+-binding in solution, may not be efficient for particles dissolution.

The Co3O4P are mixed-valence cobalt oxide particles, with Co(II) and Co(III). Therefore, destabilization of the particle surface by modifying the Co(II)/Co(III) equilibrium is probably an important step of Co3O4P dissolution, as it was described for mixed-valence iron oxides.

This prompted us to review the literature (Table 1), and to develop a strategy based on the hypotheses previously established for other metallic oxide particles dissolution. Particle dissolution depends mainly on three mechanisms: 1) protonation, in which protons are competing with the positively charged cations at the surface of the particle, 2) reduction, which leads to the destabilization of the particle surface by reducing the lattice metal cations thus modifying their preferred coordination and leading to the release of the dissolved cation and 3) chelation, acting directly at the particle surface or in solution. It is also of importance to note that a same molecule can act both as a chelator and as a redox agent, as it has been reported for ascorbate (Huang et al., 2017; Suter et al., 1991) and siderophores (Bi et al., 2010; Kraemer, 2004; Saad et al., 2017). For siderophores, literature data also propose a proton-promoted dissolution mechanisms (Kraemer, 2004).

We also combined molecules with different properties to reach a higher efficacy. Indeed, Joseph et al. demonstrated the positive effect of the combination of citric acid, EDTA and ascorbic acid for dissolving hematite at pH 2.8 (Joseph et al. 1996). Ascorbic acid initiated the dissolution by Fe(III) reduction into Fe(II) at the particle surface. In addition ascorbate can reduce Fe(III)-EDTA complexes formed in solution, and the resulting Fe(II)-EDTA complex is proposed to accelerate the reductive particle dissolution. Actually, the citric acid–EDTA–ascorbic acid was shown to completely dissolve hematite at pH 3 (Ananthan et al. 2003).

Whatever the tested molecule, the overall dissolution in ALF was always higher than in Gamble’s. In contrast, the dissolution enhancement observed with given molecules as compared to untreated controls was higher in Gamble’s than in ALF. As an example in the biphasic model, the dissolution increased 18.5 fold in the presence of ascorbate and DTPA as compared to controls in 7 days, and 2.1 fold only in ALF. The higher dissolution obtained in ALF suggests that the effect of pH is dominating over the effect of (reductive) complexation in the process of Co3O4P dissolution, at least at short incubation times. This is not true anymore at longer incubation times, as demonstrated by the significantly higher dissolution rate observed for Co3O4P dissolution at day 28 in presence of DFOB with or without ascorbate or oxalate, and with ascorbate and 50 mM EDTA (Figure 5) as compared to the control. On the other hand, the very low level of Co3O4P dissolution in Gamble’s might be explained by a competition for complexation between the Ca and Mg cations present at high concentration in the medium and Co towards the added chelating molecules. We tested this hypothesis by incubating Co3O4P in HEPES and EDTA in presence of Ca2+ and Mg2+ at concentrations found in Gamble's, and the 7-day dissolution was reduced 32 fold in the presence of these two cations (data not shown). The low but significant Co3O4P dissolution increase obtained with L-Cys and GSH in Gamble’s (Figure 2) also supports this hypothesis, since these compounds are poor Ca2+ or Mg2+ ligands. We cannot exclude however, that these compounds contribute to Co3O4P dissolution by other mechanisms, such as a redox effect. In Gamble’s medium, the dissolution process could also be inhibited by possible “passivation” agents such as proteins or small molecules as phosphate, which could irreversibly bind to the particles and protect their surface against degradation.

Overall, our results strongly suggest that the combination of two molecules with different mechanisms of action on cobalt oxide particles provides an effective strategy to increase their dissolution in the two lung fluid surrogates (Tables 2 and 3). Of particular interest is the important long-term effect observed in the dynamic assay in ALF, since these conditions correspond to the main retention compartment for Co3O4P in the lungs, following macrophage uptake. Ascorbate associated with chelating molecules as EDTA, DTPA or DFOB showed a higher efficacy than when used alone. This suggests that, *in vivo*, such combinations would be of great interest by promoting the particles dissolution using a redox mechanisms, coupled by the chelation of the dissolved Co2+ ions. Translocation from lungs to blood would consequently occur, accelerating lung clearance and decreasing the time of irradiation. The subsequent committed effective dose in case of inhalation of radioactive cobalt compounds would thus be limited. An important issue in the identification of new decorporating drugs, is their potential toxicity. Indeed, a crucial point in the development of a treatment for use in humans is its absence of toxicity. In this respect, it is important to note that among the molecules used in combination that allow the highest dissolution rate of Co3O4P, DTPA, EDTA, ascorbate and DFOB are FDA approved molecules. Although the unspecific chelation of other metallic ions cannot be excluded, no major side effects have been reported for these molecules. Ca-DTPA has been used in workers contaminated with actinides for few decades. As reported by the FDA administration and in a case study (Grappin et al. 2007), no evidence for side effects in 95% of the treated workers was reported, even after long term administration.

**Conclusions**

In the present study, we evaluated the ability of various molecules to increase the dissolution of Co3O4P in lung fluid surrogates. Dissolution was assessed using two complementary acellular *in vitro* models, representative of retention compartments following pulmonary contamination with poorly soluble cobalt particles. We first demonstrated that DTPA, the currently recommended decorporating treatment, had no significant effect on the dissolution of Co3O4P. We then showed that combining redox active molecules with chelating agents led to a better efficacy for Co3O4P dissolution than each molecule used alone as already reported for the dissolution of mixed-valence iron oxide particles. From the present work, a small set of combinations involving FDA- approved molecules, very promising for new decorporation strategies, were identified and can be now tested on main cellular targets, such as pulmonary macrophages.

**References**

Afonso, M.D., Morando, P.J., Blesa, M.A., Banwart, S., Stumm, W., 1990. The Reductive Dissolution of Iron-Oxides by Ascorbate - the Role of Carboxylate Anions in Accelerating Reductive Dissolution. Journal of Colloid and Interface Science 138, 74-82.

ASN, 2008. Intervention médicale en cas d’événement nucléaire ou radiologique. https://[www.asn.fr/Professionnels/Les-Guides-de-l-ASN/Guide-national-d-intervention-medicale-en-cas-d-evenement-nucleaire-ou-radiologique](http://www.asn.fr/Professionnels/Les-Guides-de-l-ASN/Guide-national-d-intervention-medicale-en-cas-d-evenement-nucleaire-ou-radiologique).

Barceloux, D.G., 1999. Cobalt. J Toxicol Clin Toxicol 37, 201-206.

Bi, Y., Hesterberg, D.L., Duckworth, O.W., 2010. Siderophore-promoted dissolution of cobalt from hydroxide minerals. Geochimica et Cosmochimica Acta 74, 2915-2925.

Bornhorst, J.A., Falke, J.J., 2000. Purification of proteins using polyhistidine affinity tags. Methods Enzymol 326, 245-254.

Cho, W.S., Duffin, R., Thielbeer, F., Bradley, M., Megson, I.L., MacNee, W., Poland, C.A., Tran, C.L., Donaldson, K., 2012. Zeta Potential and Solubility to Toxic Ions as Mechanisms of Lung Inflammation Caused by Metal/Metal Oxide Nanoparticles. Toxicological Sciences 126, 469-477.

Collier, C.G., Pearce, M.J., Hodgson, A., Ball, A., 1992. Factors affecting the in vitro dissolution of cobalt oxide. Environ Health Perspect 97, 109-113.

Davis, K., Marsh, J.W., Gerondal, M., Bailey, M.R., Le Guen, B., 2007. Assessment of intakes and doses to workers followed for 15 years after accidental inhalation of 60CO. Health Phys 92, 332-344.

Delangle, P., Mintz, E., 2012. Chelation therapy in Wilson’s disease: from D-Penicillamine to the design of selective bioinspired intracellular Cu(I) chelators. Dalton transactions 41, 6359-6370.

Dubbin, W.E., Bullough, F., 2017. Dissolution of Al-Substituted Goethite in the Presence of Ferrichrome and Enterobactin at pH 6.5. Aquatic Geochemistry 23, 61-74.

Fisher, D.R., Dunavant, B.G., 1978. Internal decontamination of radiocobalt. Health Phys 35, 279-285.

Ghasemi, K., Rezvani, A.R., Shokrollahi, A., Moghimi, A., Gavahi, S., Garcia-Granda, S., Mendoza-Merono, R., 2014. A proton transfer and a cobalt(II) compound including 2,6-pyridinedicarboxylate and o-phenylenediamine ions: Synthesis, characterization, crystal structure and solution study. Comptes Rendus Chimie 17, 1221-1229.

Giampreti, A., Lonati, D., Ragghianti, B., Ronchi, A., Petrolini, V.M., Vecchio, S., Locatelli, C.A., 2016. N-Acetyl-Cysteine as Effective and Safe Chelating Agent in Metal-on-Metal Hip-Implanted Patients: Two Cases. Case Rep Orthop 2016, 8682737.

Gremy, O., Tsapis, N., Chau, Q., Renault, D., Abram, M.C., Van der Meeren, A., 2010. Preferential decorporation of americium by pulmonary administration of DTPA dry powder after inhalation of aged PuO(2) containing americium in rats. Radiat Res 174, 637-644.

Griffiths, N., Van der Meeren, A., Angulo, J., Vincent-Naulleau, S., in press. Research on the Radiotoxiocology of plutonium: consideration of the 3Rs – Replace, Reduce, Refine. Health Physics Journal.

Griffiths, N.M., Coudert, S., Moureau, A., Laroche, P., Angulo, J.F., Van der Meeren, A., 2016. Forecasting the In Vivo Behavior of Radiocontaminants of Unknown Physicochemical Properties Using a Simple In Vitro Test. Health Phys 111, 93-99.

Guilmette, R.A., Muggenburg, B.A., 1993. Decorporation therapy for inhaled plutonium nitrate using repeatedly and continuously administered DTPA. Int J Radiat Biol 63, 395-403.

Hedberg, Y., Gustafsson, J., Karlsson, H.L., Moller, L., Wallinder, I.O., 2010. Bioaccessibility, bioavailability and toxicity of commercially relevant iron- and chromium-based particles: in vitro studies with an inhalation perspective. Particle and Fibre Toxicology 7.

Huang, X.P., Hou, X.J., Song, F.H., Zhao, J.C., Zhang, L.Z., 2017. Ascorbate Induced Facet Dependent Reductive Dissolution of Hematite Nanocrystals. Journal of Physical Chemistry C 121, 1113-1121.

ICRP, 2016. Occupational Intakes of Radionuclides : Part 2., Annals of the ICRP Publication 134. .

Joseph, S., Visalakshi, G., Venkateswaran, G., Moorthy, P.N., 1996. Dissolution of haematite in citric acid-EDTA-ascorbic acid mixtures. Journal of Nuclear Science and Technology 33, 479-485.

Jurisson, S.S., Benedict, J.J., Elder, R.C., Deutsch, E., 1983. Calcium affinity of coordinated diphosphonate ligands. Single-crystal structure of [(en)2Co(O2P(OH)CH2P(OH)O2)]ClO4.H2O. Implications for the chemistry of technetium-99m-diphosphonate skeletal imaging agents. Inorganic Chemistry 22, 1332-1338.

Kastury, F., Smith, E., Juhasz, A.L., 2017. A critical review of approaches and limitations of inhalation bioavailability and bioaccessibility of metal(loid)s from ambient particulate matter or dust. Sci Total Environ 574, 1054-1074.

Kraemer, S.M., 2004. Iron oxide dissolution and solubility in the presence of siderophores. Aquatic Sciences 66, 3-18.

Kreyling, W.G., Andre, S., Collier, C.G., Ferron, G.A., Metivier, H., Schumann, G., 1991. Interspecies Comparison of Lung Clearance after Inhalation of Monodisperse, Solid Cobalt Oxide Aerosol-Particles. Journal of Aerosol Science 22, 509-535.

Kreyling, W.G., Cox, C., Ferron, G.A., Oberdorster, G., 1993. Lung clearance in Long-Evans rats after inhalation of porous, monodisperse cobalt oxide particles. Exp Lung Res 19, 445-467.

Lakind, J.S., Stone, A.T., 1989. Reductive Dissolution of Goethite by Phenolic Reductants. Geochimica Et Cosmochimica Acta 53, 961-971.

Le Guen, B., Ansoborlo, E., 2005. Le cobalt et ses isotopes [in French]. Toxicologie-Pathologie professionnelle, 1-11.

Levitskaia, T.G., Creim, J.A., Curry, T.L., Luders, T., Morris, J.E., Woodstock, A.D., Levinson, B., Thrall, K.D., 2010a. Evaluation of Cuprimine and Syprine for decorporation of (60)Co and (210)Po. Health Phys 98, 471-479.

Levitskaia, T.G., Creim, J.A., Curry, T.L., Luders, T., Peterson, J.M., Thrall, K.D., Levinson, B., 2011. Evaluation of Cuprimine(R) and Syprine(R) for decorporation of radioisotopes of cesium, cobalt, iridium and strontium. Health Phys 101, 118-127.

Levitskaia, T.G., Morris, J.E., Creim, J.A., Woodstock, A.D., Luders, T., Curry, T.L., Thrall, K.D., 2010b. Aminothiol receptors for decorporation of intravenously administered (60)Co in the rat. Health Phys 98, 53-60.

Llobet, J.M., Domingo, J.L., Corbella, J., 1986. Comparison of the effectiveness of several chelators after single administration on the toxicity, excretion and distribution of cobalt. Arch Toxicol 58, 278-281.

Llobet, J.M., Domingo, J.L., Corbella, J., 1988. Comparative effects of repeated parenteral administration of several chelators on the distribution and excretion of cobalt. Res Commun Chem Pathol Pharmacol 60, 225-233.

Lundborg, M., Falk, R., Johansson, A., Kreyling, W., Camner, P., 1992. Phagolysosomal pH and dissolution of cobalt oxide particles by alveolar macrophages. Environ Health Perspect 97, 153-157.

Marques, M.R.C., Loebenberg, R., Almukainzi, M., 2011. Simulated Biological Fluids with Possible Application in Dissolution Testing. Dissolution Technologies 18, 15-28.

Matsumoto, M., Suzuki, M., Kano, H., Aiso, S., Yamazaki, K., Fukushima, S., 2012. Carcinogenicity of ortho-phenylenediamine dihydrochloride in rats and mice by two-year drinking water treatment. Archives of Toxicology 86, 791-804.

Ortega, R., Bresson, C., Darolles, C., Gautier, C., Roudeau, S., Perrin, L., Janin, M., Floriani, M., Aloin, V., Carmona, A., Malard, V., 2014. Low-solubility particles and a Trojan-horse type mechanism of toxicity: the case of cobalt oxide on human lung cells. Particle and Fibre Toxicology 11, 14.

Panias, D., Taxiarchou, M., Paspaliaris, I., Kontopoulos, A., 1996. Mechanisms of dissolution of iron oxides in aqueous oxalic acid solutions. Hydrometallurgy 42, 257-265.

Pazzaglia, U.E., Apostoli, P., Congiu, T., Catalani, S., Marchese, M., Zarattini, G., 2011. Cobalt, chromium and molybdenum ions kinetics in the human body: data gained from a total hip replacement with massive third body wear of the head and neuropathy by cobalt intoxication. Arch Orthop Trauma Surg 131, 1299-1308.

Pelfrene, A., Cave, M.R., Wragg, J., Douay, F., 2017. In Vitro Investigations of Human Bioaccessibility from Reference Materials Using Simulated Lung Fluids. International Journal of Environmental Research and Public Health 14.

Pujol, A.M., Gateau, C., Lebrun, C., Delangle, P., 2009. A Cysteine-Based Tripodal Chelator with a High Affinity and Selectivity for Copper(I). Journal of the American Chemical Society 131, 6928-6929.

Pujol, A.M., Gateau, C., Lebrun, C., Delangle, P., 2011. A series of tripodal cysteine derivatives as water-soluble chelators highly selective for Copper (I). Chemistry- A European Journal 17, 4418-4428.

REMM, Radiation Countermeasures for Treatment of Internal Radiation Contamination. .

Rump, A., Becker, B., Eder, S., Lamkowski, A., Abend, M., Port, M., 2018. Medical management of victims contaminated with radionuclides after a “dirty bomb” attack. Military Medical Research 5, 27.

Russell, W., Burch, R., 1959. Ch.4. The sources, incidences and removal of inhumanity., In: London, K.M. (Ed.), The principle of humane experimental technique. .

Saad, E.M., Sun, J.Y., Chen, S.O., Borkiewicz, O.J., Zhu, M.Q., Duckworth, O.W., Tang, Y.Z., 2017. Siderophore and Organic Acid Promoted Dissolution and Transformation of Cr(III)-Fe(III)-(oxy)hydroxides. Environmental Science & Technology 51, 3223-3232.

Staack, G., Cheng, Y.-S., Zhou, Y., LaBone, T., 2017. Determination of In Vitro Lung Solubility and Intake-to-Dose Conversion Factors for Tritiated LaNi4.15Al0.85 and 13X Zeolite. Fusion Science and Technology 71, 570-574.

Stefaniak, A.B., 2010. Persistence of tungsten oxide particle/fiber mixtures in artificial human lung fluids. Particle and Fibre Toxicology 7.

Stone, A.T., Morgan, J.J., 1984. Reduction and Dissolution of Manganese(Iii) and Manganese(Iv) Oxides by Organics .2. Survey of the Reactivity of Organics. Environmental Science & Technology 18, 617-624.

Suter, D., Banwart, S., Stumm, W., 1991. Dissolution of Hydrous Iron(Iii) Oxides by Reductive Mechanisms. Langmuir 7, 809-813.

Uboldi, C., Orsiere, T., Darolles, C., Aloin, V., Tassistro, V., George, I., Malard, V., 2016. Poorly soluble cobalt oxide particles trigger genotoxicity via multiple pathways. Particle and Fibre Toxicology 13, 5.

Van der Meeren, A., Angulo, J.F., Bohand, S., Griffiths, N.M., 2019. A quick and simple in vitro assay to predict bioavailability of actinides following accidental exposure. Toxicology in Vitro 58, 142-149.

Weber, W., Doyle-Eisele, M., Seilkop, S.K., Guilmette, R., 2012. Biokinetics of Systemically Distributed 60Co in the Rat: An Experimental Model Useful in Evaluating Medical Countermeasures for Internal Contamination. Health Phys 103, 474-483.

Yang, L.Q., Crans, D.C., Miller, S.M., la Cour, A., Anderson, O.P., Kaszynski, P.M., Godzala, M.E., Austin, L.D., Willsky, G.R., 2002. Cobalt(II) and cobalt(III) dipicolinate complexes: Solid state, solution, and in vivo insulin-like properties. Inorganic Chemistry 41, 4859-4871.

Zhao, J., Liu, Y., Pan, B., Gao, G.Q., Liu, Y., Liu, S.Q., Liang, N., Zhou, D.D., Vijver, M.G., Peijnenburg, W.J.G.M., 2017. Tannic acid promotes ion release of copper oxide nanoparticles: Impacts from solution pH change and complexation reactions. Water Research 127, 59-67.

Zinder, B., Furrer, G., Stumm, W., 1986. The Coordination Chemistry of Weathering .2. Dissolution of Fe(Iii) Oxides. Geochimica Et Cosmochimica Acta 50, 1861-1869.

Zylicz, E., Zablotna, R., Geisler, J., Szot, Z., 1975. Effects of DTPA on the deposition of 65Zn, 60Co and 144Ce in pregnant rat and in foetoplacental unit. Int J Radiat Biol Relat Stud Phys Chem Med 28, 125-136.